Atlas FDA

NEVISENSE

FDA premarket approval P150046 · decided 2017-06-28

Approval details

PMA number
P150046
Trade name
NEVISENSE
Generic name
Electrical Impedance Spectrometer
Applicant
Scibase AB
Date received
2015-12-07
Decision date
2017-06-28
Days to decision
569 days
Decision code
APRL
Product code
ONV
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Stockholm
Statement
Approval for the Nevisense. This device is indicated for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologist chooses to obtain additional information when considering biopsy. Nevisense should not be used on clinically obvious melanoma. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional informa

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.